Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study

IntroductionMitotane, the only drug approved by the Food and Drug Administration (FDA) for the treatment of adrenocortical carcinoma, is associated with several side effects including neurotoxicity. The aim of our study is to investigate the relationship between mitotane plasma levels and neurologic...

Full description

Bibliographic Details
Main Authors: Marilda Mormando, Edvina Galiè, Marta Bianchini, Rosa Lauretta, Giulia Puliani, Antonio Tanzilli, Umberto Anceschi, Giuseppe Simone, Gianluca Petreri, Giuliana Graziano, Andrea Pace, Marialuisa Appetecchia
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
mitotane
adrenocortical carcinoma
neurological toxicity
electroencephalogram
P300
neuropsychological testing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1222002/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1222002/full

Similar Items